Clinical Autonomic Research

, Volume 18, Supplement 1, pp 25–29 | Cite as

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension

The European experience
  • Christopher J. MathiasEmail author


Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy and also in Parkinson’s disease. Treatment is ideally two pronged, using non-pharmacological and pharmacological measures.

Drug treatment ideally is aimed at restoring adequate amounts of the neurotransmitter noradrenaline. This often is not achievable because of damage to sympathetic nerve terminals, to autonomic ganglia or to central autonomic networks. An alternative is the use of sympathomimetics (that mimic the effects of noradrenaline, but are not identical to noradrenaline), in addition to other agents that target physiological mechanisms that contribute to blood pressure control.

L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Experience in Caucasians and in Europe is limited mainly to patients with dopamine beta hydroxylase deficiency. This review focuses on two studies performed in Europe, and provides information on its efficacy, tolerability and safety in patients with pure autonomic failure, multiple system atrophy and Parkinson’s disease. It also addresses the issue of whether addition of dopa decarboxylase inhibitors, when combined with l-dopa in the treatment of the motor deficit in Parkinson’s disease, impairs the pressor efficacy of Droxidopa.

Key words

l-dihydroxyphenylserine orthostatic hypotension autonomic failure noradrenaline multiple system atrophy Parkinson's disease 



Major investigators have included Professor P Cortelli, Professor J M Senard, and many colleagues in participating centres. Disclosure Prof. C.J. Mathias was the Principal Investigator of both studies reviewed, which were supported by Sumitomo Pharmaceuticals, Japan. He is a Consultant for Chelsea Therapeutics, USA.


  1. 1.
    Heims HC, Martin NH, Critchley HD, Jäger HR, Mathias CJ, Cipolotti L. (2006). Cognitive functioning in orthostatic hypotension due to pure autonomic failure. Clin Aut Res 16:113–120CrossRefGoogle Scholar
  2. 2.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 108:724–728PubMedCrossRefGoogle Scholar
  3. 3.
    Lahrmann H, Cortelli, Hilz M, Mathias CJ, Struhal W, Tassinari M. (2006) European Federation of Neurological Society guidelines on the diagnosis and management of orthostatic hypotension. Europ J Neurol 13:930–6Google Scholar
  4. 4.
    Man in’t Veld AJ, Van den Meiracker AH, Boomsma F, Schalekamp MADH. (1987) Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine beta-hydroxylase deficiency. Lancet ii:1172–5Google Scholar
  5. 5.
    Mathias CJ, Bannister R, Cortelli P, Heslop K, Polak J, Raimbach SJ, Springall DB, Watson L. (1990) Clinical autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta-hydroxylase. QJM, New Series 75(278):617–633Google Scholar
  6. 6.
    Mathias CJ, Mallipeddi R, Bleasdale-Barr K. (1999) Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 246(10):893–898PubMedCrossRefGoogle Scholar
  7. 7.
    Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. (2001) L-threo-dihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res 11:235–242CrossRefGoogle Scholar
  8. 8.
    Mathias CJ, Bannister R. (2002) Dopamine beta-hydroxylase deficiency. In: Mathias CJ, Bannister R, (eds.) Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 4th ed. Oxford and New York: Oxford University Press pp. 387–401Google Scholar
  9. 9.
    Mathias CJ. (2003) Autonomic diseases – clinical features and laboratory evaluation. JNNP 74:31–41Google Scholar
  10. 10.
    Mathias CJ. (2003) Autonomic diseases – Management. JNNP 74:42–47Google Scholar
  11. 11.
    Mathias CJ. (2005) Cardiovascular Autonomic Dysfunction in Parkinson’s Disease and Parkinsonian Syndromes. In: Ebadi M, Pfeiffer RF. (Eds.) Parkinson’s Disease. CRC Press LLC, New York 295–317Google Scholar
  12. 12.
    Mathias CJ. (2006) Orthostatic hypotension and orthostatic intolerance. In: DeGroot LJ, Jameson JL, de Kretser D, Grossman AB, Marshall JC, Melmed S, Potts JT, Weir GC. (Eds.) Endocrinology. 5th edition. Elsevier Saunders, Philadelphia PA, USA 2613–2632Google Scholar
  13. 13.
    Mathias CJ, Senard JM, Cortelli P. (2007) A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson’s disease. Clin Aut Res 17:272. abstractGoogle Scholar
  14. 14.
    Narabayashi H, Nakanishi T. (1987) Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eva1 15:423–457Google Scholar
  15. 15.
    Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG, Robertson RM. (1987) Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine New Engl. J. Med 314:1494–7CrossRefGoogle Scholar
  16. 16.
    Sobue I, Senda Y, Hirayama K, et al. (1987) Clinical pharmacological evaluation of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Shy-Drager’s syndrome and its related diseases. A nationwide double-blind comparative study. Jpn J Clin Exp Med 141:353–378Google Scholar
  17. 17.
    Suzuki T, Higa S, Sakoda S, et al. (1982) Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol 23:463–468PubMedCrossRefGoogle Scholar
  18. 18.
    Yanagisawa N, Ikeda S, Hashimoto T, Hanyu N, Nakagawa S, Fujimori N, Ushiyama M. (1998) Effects of L-threo-Dops on orthostatic hypotension in Parkinson’s disease. No To Shinkei 50:157–63PubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Neurovascular Medicine Unit Faculty of MedicineImperial College London at St Mary’s HospitalLondonUK
  2. 2.National Hospital for Neurology and Autonomic Unit, NeurosurgeryInstitute of Neurology University College LondonLondonUK

Personalised recommendations